Hospitals that administer the expensive new CAR-T gene therapy are not required to participate in a clinical registry or study aimed at determining whether real-world results mirror those from clinical trials used to get the cancer drugs approved, according to the national coverage determination CMS published Wednesday (Aug. 7) . Sources following the CAR-T decision said political appointees did not want to require so-called coverage with evidence development, and the nearly two-month delay in announcing the national coverage determination was...